Correlation Between Swedish Orphan and Moberg Pharma

Can any of the company-specific risk be diversified away by investing in both Swedish Orphan and Moberg Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Swedish Orphan and Moberg Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Swedish Orphan Biovitrum and Moberg Pharma AB, you can compare the effects of market volatilities on Swedish Orphan and Moberg Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Swedish Orphan with a short position of Moberg Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Swedish Orphan and Moberg Pharma.

Diversification Opportunities for Swedish Orphan and Moberg Pharma

0.55

Correlation Coefficient

Swedish Orphan  Moberg Pharma

Very weak diversification

The 3 months correlation between Swedish and Moberg is 0.55. Overlapping area represents the amount of risk that can be diversified away by holding Swedish Orphan Biovitrum and Moberg Pharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Moberg Pharma AB and Swedish Orphan is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Swedish Orphan Biovitrum are associated (or correlated) with Moberg Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Moberg Pharma AB has no effect on the direction of Swedish Orphan i.e., Swedish Orphan and Moberg Pharma go up and down completely randomly.

Pair Corralation between Swedish Orphan and Moberg Pharma

Assuming the 90 days trading horizon Swedish Orphan Biovitrum is expected to generate 0.49 times more return on investment than Moberg Pharma. However, Swedish Orphan Biovitrum is 2.05 times less risky than Moberg Pharma. It trades about -0.06 of its potential returns per unit of risk. Moberg Pharma AB is currently generating about -0.13 per unit of risk. If you would invest  31,080  in Swedish Orphan Biovitrum on December 23, 2024 and sell it today you would lose (2,040) from holding Swedish Orphan Biovitrum or give up 6.56% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Swedish Orphan Biovitrum  vs.  Moberg Pharma AB

Swedish Orphan Biovitrum

Risk-Adjusted Performance

Very Weak

Over the last 90 days Swedish Orphan Biovitrum has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.

Moberg Pharma AB

Risk-Adjusted Performance

Very Weak

Over the last 90 days Moberg Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Swedish Orphan and Moberg Pharma

The main advantage of trading using opposite Swedish Orphan and Moberg Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Swedish Orphan position performs unexpectedly, Moberg Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Moberg Pharma will offset losses from the drop in Moberg Pharma's long position.

The idea behind Swedish Orphan Biovitrum and Moberg Pharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.